1.	Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-306, NCT01147939
2.	A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-106, NCT00405743
3.	A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-204, NCT00831636
4.	Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-201, NCT00232726
5.	A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-202, Grantor: CDER, IND/IDE Number: NA, NCT00498407
6.	Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-203, NCT00498836
7.	A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP4055-205, NCT01035502